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Type I and type II interferons (IFNs) can act synergistically to activate the transcription of the 2-SA synthetase gene. We used in vivo functional 
assays of sequences from the gene promoter region to determine which DNA segment mediates the gene induction by IFNy and the synergistic 
effect. We found that the type I IFN-inducible enhancer (or IRS) of the 2-5A synthetase gene also confers inducibility by type II IFN to a reporter 
CAT gene, though the time course and dose response of the induction by the two IFNs are quite different. A clear synergism of the two IFNs 
in stimulating the IRS is observed at low doses of the two IFNs. 
2-5A Synthetase; Type I interferon-inducible enhancer synergistic activation type I interferon; Type II interferon 
1. INTRODUCTION 
The 2-5A synthetase nzymatic activity is inducible 
by type I(cu,p) interferons (IFNs) and type II(y) IFNs in 
most cell lines [l]. The two types of IFNs differ, 
however, notably in their structure, their cell surface 
receptors, and their biological activities [2,3]. It is 
therefore logical that the characteristics of induction of 
the cloned 2-SA synthetase mRNAs [4] by the two IFNs 
are not similar [5,6]. The mRNAs are induced much 
less by IFNy than by type I IFNs [5,6]. In HeLa cells, 
their induction by IFNy can be abolished by the protein 
synthesis inhibitor cycloheximide, while their induction 
by IFNcv is, in general, not sensitive to cycloheximide 
[5] and considered as a direct effect on transcription 
(71. At the same time, it was described that the two 
IFNs can synergize to produce antiviral and antigrowth 
effects [8,9] and induce the 2-5A synthetase [lo-141. 
The synergistic effect is particularly visible in cells par- 
tially resistant o type I IFNs [12], and has been shown 
to occur at the level of gene transcription [ 13,141. That 
the synergistic effect could result from a change in IFN 
receptors is not likely [11,12]. 
It was therefore important to assess whether the ac- 
tivation of the gene by the two types of IFNs is 
mediated by the same or by distinct DNA sequence 
elements. To answer this question, we have tested the 
ability of different segments of the 2-5A synthetase 
promoter, coupled to a reporter gene, to mediate the in- 
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duction by either type of IFN or their combination 
upon transfection in HeLa cells. 
2. MATERIALS AND METHODS 
2.1. Cell culture, transfections and CAT assays 
HeLa cells were grown as monolayers. For transient transfection 
experiments, cells were transfected at half-confluency with supercoil- 
ed plasmid DNA by the Cap04 precipitation method, as previously 
described [15-171. After 12 h, the medium was changed, and the cells 
were induced for 24 h by 200 IU/ml of recombinant human IFN@l, 
500 IU/ml recombinant human IFNy, or left untreated. To obtain 
permanently transformed HeLa cells, 50% confluent cells in lo-cm 
plates were transfected simultaneously by 19 fig of XhE-IRS TK- 
CAT [15] and 1 Gg of pSVz-neo plasmid [18], the latter conferring 
resistance to the antibiotic neomycin (G-418, Sigma). After 3 weeks 
of selection in the presence of 500 gg/ml G418, 100 G-418 resistant 
clones were pooled. The integration of the plasmid XhE-IRS TK- 
CAT was checked by Southern blotting [19]. 24 h after induction the 
cells were collected and CAT activity (expressed as percent acetyla- 
tion of chloramphenicol) measured [131. 
2.2. Plasmids 
The pGEM CAT-E and 5431 vectors containing the -748/+82 
and - 159/ +82 fragments of the 2-5A synthetase promoter, respec- 
tively, fused in frame to the CAT coding sequences in the pGEM 
CAT-O vector were constructed as described [161. pGEM TK CAT-O 
was obtained by cloning the HSV TK gene - 109/ +51 promoter frag- 
ment in front of the CAT gene in pGEM CAT-O [16,17]. hE-IRS TK- 
CAT or moE-IRS TK-CAT were obtained by cloning synthetic IRS 
regions (- 102/ -87 of the human 2’-5’ A synthetase gene, TGAG- 
GAAACGAAACCA, or -741-59 of the mouse 2-5A synthetase 
gene, TCGGGAAATGGAAACT) in the multilinker of the pGEM 
TK CAT-O plasmid, upstream of the TK promoter (171. The XhE- 
IRS TK-CAT contains six copies of the synthetic human IRS, 
forming the following nucleotide sequence cloned in the BamHl site 
of the polylinker in front of the TK gene (171: ggatCTGAGGAAA- 
CGAAACCAg ( gaTCCTGGGCGTTTCCTCA ) sgatccaga. 
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2.3. RNA preparation and Sl-m&ease analysis 
Total cellular RNA was prepared from HeLa cells by the hot 
phenol method [17] from two 9-cm plates, 36 h after transfection, 
and 12 h after induction of 200 IU/ml IFN;Bl, 500 III/ml IFNy, or 
no IFN, in the presence or absence of 50 rg/ml of cycloheximide for 
12 h. To prepare a labelled probe, the EcoRI fragment of the plasmid 
pGEM TK-CAT-O was first inserted in the EcoRI site of the M13+ 
Bluescript vector (Stratagene). The non-coding strand was then 
labelled with aSZP-dCTP by the Klenow enzyme from the T7 primer, 
cut with HindIII, and isolated from a denaturing polyacrylamide gel. 
The annealing to the RNA and Sl nuclease analysis were as described 
[171. 
3. RESULTS 
3.1. Sequences governing the transcriptional response 
to ,8 and y IFNs 
The CAT activities were measured in extracts of cells 
transfected by various plasmid DNAs, and treated by 
IFNs p or y (section 2). The ratio of the CAT activities 
in the presence of IFNs relative to the activities in the 
absence of IFN are shown in Fig. 1. We observe that 
the segments -748/ +82 (pGEM CAT E) or - 159/ +82 
(543 1 CAT) of the 2-5A synthetase promoter both have 
the ability to render the CAT gene inducible by IFN,& 
and IFNy, IFNy being much less efficient in this pro- 
cess. Inducibility by IFNy is also visible when only a 
14-bp segment of the human 2-5A synthetase promoter 
( - 102/ -87), hE IRS TK CAT), or of the mouse pro- 
moter [17] (( -74/ -59), mE IRS TK CAT), was cloned 
in front of the TK-CAT chimeric construct (Fig. 1). 
This element has been identified as a type I IFN- 
responsive sequence or IRS [16,17]. 
A higher induction ratio, due to a higher expression 
of the CAT, was observed with both IFNs when a 
multimer of the hE IRS was in front of the TK-CAT 
chimeric construct (XhE IRS TK CAT) (Fig. 1). No 
IFN effect was observed with the control vectors 
pGEM CAT-O, or pGEM TK CAT-O (Fig. l), or other 
vectors including a 2-5A synthetase promoter fragment 
which did not contain the IRS (-206/-109, not 
shown). In the constructs where only the IRS fragment 
is present, as when the whole promoter is used, IFNy 
induces less CAT activity than IFNfl. 
3.2. The induction of CAT mRNA by IFNy is 
inhibited by cycloheximide 
We isolated RNA from HeLa cells transfected by the 
XhE IRS TK CAT plasmid and treated by IFNs in the 
presence or absence of cycloheximide. After hybridiza- 
tion of the RNAs with a radiolabelled DNA probe com- 
plementary to the 5’ regions of the CAT gene and TK 
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Fig. 1. Two variants of the IRS are able to mediate the effects of both types of IFNs. Subconfluent HeLa cells were transiently transfected by 
the constructs described in section 2. The thick arrows indicate the orientations of the IRS. The dashed arrows correspond to the murine IRS. 
The thin arrows show the location of RNA start sites. The values given are the average of several transfections experiments. The differences from 
the control plasmids (pGEM CAT-O and pGEM TK CAT-O) are significant at the threshold of 1% with the Student’s t-test. 
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promoter [ 171, the CAT mRNA concentration was 
determined by its ability to protect this probe from Sl 
nuclease digestion [19]. We see in Fig. 2 that in the 
absence of cyclohe~~de, the CAT mRNA was induc- 
ed by IFNfl (8.4-fold) and by IFNy (3.0-fold). The 
mRNA, like the CAT activity was less induced by 
IFNy, showing that the differential effect is really 
transcriptional. The CAT mRNA was also increased by 
cycloheximide treatment alone (Fig. 2). This increase 
does not involve the IRS, since it is observed also in 
cells transfected by the pGEM TK CAT-O vector (not 
shown). In cells treated with IFN and cycloheximide, 
IFN/3 induced the CAT mRNA above the basal level 
(4.5-fold stimulation) while IFNy did not stimulate, or 
even depressed, the CAT mRNA level. 
3.3. Combined effects of the two IFNs on the 
activation of the IRS 
To perform this study, which involves a large 
number of assays at different doses of IFN, the use of 
HeLa cells permanently transformed by the XhE IRS 
TK CAT vector was preferred to transient transfec- 
tions. Fig. 3A shows the ratios of induction of the CAT 
activity brought by each IFN separately, after 48 h of 
treatment. At 24 h of treatment, the induction by IFNy 
was lower than after 48 h treatment (by 2-fold), while 
the induction by IFN# was similar or higher (not 
shown). IFNy is therefore unable by itself to stimulate 
the IRS to the levels of maximal induction obtained 
with IFN/3. When the two IFNs were mixed, however, 
a synergistic effect could be obtained, depending on the 
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Fig. 2. Activation of the XhEIRS TK promoter by IFNy but not by IFNB requires protein synthesis, Sl m&ease analysis of the transcripts in 
HeLa cells transiently transfected by the XhElRS TK-CAT plasmid and treated (+ ) or not (- ) with cycioheximide in the absence (0) or presence 
of 200 U/ml IFN@ or 500 U/ml IFNy, for 12 h. Fragments fl and f2 protected by transcripts are schematized. I2 corresponds to transcripts 
starting at the TK cap site. P = probe without Sl. M = MspII-cut PBR 322 size markers, “P end-labelled. t = Probe annealed to tRNA before Si. 
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Fig. 3. Dose- and time-dependent effects of the IFNs, added 
separately or simultaneously, on CAT activity in XhE-IRS TK-CAT 
transformed cells. Subconfluent HeLa cells permanently transformed 
by XhEIRS TK-CAT were treated for different times with several 
doses of IFNfi or IFNy, or a combination of both. (A) Effects of 
increasing doses of each IFN on the induction of CAT activity in 
triplicate cell cultures was determined, and the ratio of CAT activity 
in extracts treated by IFN relative to non-treated samples was 
calculated. (B) Synergistic effect of simultaneous treatment by IFNP 
and IFNy. The CAT activity of control cultures was subtracted from 
all the corresponding values obtained with IFN. The ratio between 
the CAT activity in the presence of both IFNs and the sum of CAT 
activity obtained with each IFN added at the same doses represents 
the synergistic effect of the combination of the two IFNs. Average 
CAT activity in non-treated samples: 24 h l.l%, 48 h 2.8%. 
dose of IFN and length of treatment (Fig. 3B). A 
synergistic effect of 2- to 13-fold is observed at 
10 IU/ml of IFN,& (Fig. 3B) the effect being stronger at 
48 h. At higher concentrations of IFNP 
(100-500 IU/ml), and low concentrations of IFNy 
(l-10 IU/ml), synergism (2-3-fold) is seen at 48 h. At 
high concentrations of IFNP and IFNy, the synergism 
is seen at 24 h rather than at 48 h (Fig. 3B). 
4. DISCUSSION 
We have established that, as we have briefly reported 
before [20], the same DNA element of the 2-5A syn- 
thetase gene mediates transcriptional induction by type 
I and type II IFNs. An element homologous to the 2-5A 
synthetase IRS, also present in the 5 ‘-flanking region 
of other IFN-induced genes (6-16, and 9-27 [21], HzKd 
[22]), was able to confer inducibility by the two types 
of IFNs on a reporter gene. This statement can thus be 
now generalized. 
In addition, we show here that IFNy is less efficient 
than IFN,& in stimulating the IRS, at all the doses ex- 
amined, and that the induction of the reporter gene 
IFNy is obtained by long treatments. The same remarks 
can be made when the induction of the endogeneous 
2-5A synthetase activity [11,12,23] or mRNA is 
measured [5,6,13,14], meaning that the difference 
comes mainly from the transcriptional effects of IFNs. 
The delay in obtaining the maximal response to IFNy 
and the effect of cycloheximide suggest that the syn- 
thesis of a new protein is needed to obtain the transcrip- 
tional effect of IFNy, and that the two IFNs stimulate 
the IRS by different mechanisms. 
Furthermore, the combination of the two IFNs is not 
merely additive (Fig. 3), which might suggest that the 
two IFNs could also mutually modify the factors used 
by each of them. That the synergistic effects of the two 
IFNs is better seen after 48 h than 24 h raises the 
possibility that: (i) a protein factor induced by IFNy is 
also needed in the process of activation of the enhancer 
by IFNfl; or (ii), as previously suggested [24], down 
regulation of transcription, occurring normally at later 
times with type I IFN, is blocked by IFNy. 
Progress has been made in the characterization of 
proteins interacting with the type I IFN-inducible 
enhancer. The induction of gene transcription by type 
I IFNs has been correlated with the formation of a new 
IRS-protein complex within minutes of IFN treatment 
(ISGF3 [25], E [26]). Most interestingly, in vitro, a pro- 
tein present in extracts of HeLa cells treated by IFNy 
is able to complement he factors activated by type I 
IFNs for formation of this IFN-inducible complex [27]. 
Our results indicate that the synergistic effect that we 
observe here by functional assays in living cells could 
well be provided by such a mechanism. 
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